Lee JC, Hung J-Y, Kim Y-C, Chang G-C, Yoo SS, Yang S-H, et al. Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan. Asian Pac J Cancer Biol [Internet]. 2021 May 20 [cited 2026 Jun. 10];6(2):123-32. Available from: https://waocp.com/journal/index.php/apjcb/article/view/663